Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/572,871-Conf. #3734
Filing Date	March 21, 2006
First Named Inventor	Silvio A. CAMPAGNA
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	EISN-001CPUS

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-5,661,175	08-26-1997	Kashman et al.	
	A2*	US-5,798,355	08-25-1998	Steiner et al.	
	A3*	US-6,057,297	05-02-2000	Politi et al.	
	A4*	US-6,143,721	11-07-2000	Janssen et al.	
	A5*	US-6,153,590	11-28-2000	Andersen et al.	

U.S. Applications

Examiner Initials*	Cite No.[1]	Application No. Number-Kind Code[2] (*if known*)	Filing Date MM-DD-YYYY	Patent No.	Recorded Date MM-DD-YYYY
	1			7,064,211	01-20-2006
	2	11/340256	01-26-2006		
	3			7,192,972	03-20-2007
	4	11/701969	02-02-2007		
	5	11/296920	12-07-2005		
	6	11/418110	05-05-2006		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	B1	DE-4016994	11-28-1991	Bayer AG		Abstr.
	B2	JP-8-73444	03-19-1996	Fujisawa Pharmaceutical Co., et al.		Abstr.
	B3	WO-96/33211-A1	10-24-1996	University of British Columbia		
	B4	WO-97/43305-A1	11-20-1997	Agouron Pharmaceuticals, Inc.		
	B5	WO-98/13375-A1	04-02-1998	Gesellschaft für Biotechnologische Forschung MBH (GBF)		
	B6	WO-99/31122-A1	06-24-1999	Agouron Pharmaceuticals, Inc.		
	B7	WO-99/32509-A2	07-01-1999	The University of British Columbia		
	B8	WO-99/65299-A1	12-23-1999	Smithkline Beecham Corporation		
	B9	WO-01/18032-A2	03-15-2001	BASF Aktiengesellschaft et al.		
	B10	WO-01/79167-A2	10-25-2001	Agouron Pharmaceuticals, Inc.		
	B11	WO-03/008378-A1	01-30-2003	F. Hoffmann-La Roche AG		
	B12	WO-03/082268-A2	10-09-2003	Eisai Co. Ltd.		
	B13	DE-10230874	01-22-2004	Morphochem AG Aktiengesellschaft für kombinatorische Chemie		Abstr.
	B14	WO-04/047615-A2	06-10-2004	Wyeth		
	B15	WO-04/048527-A2	06-10-2004	Wyeth		

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/572,871-Conf. #3734
				Filing Date	March 21, 2006
				First Named Inventor	Silvio A. CAMPAGNA
(Use as many sheets as necessary)				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	EISN-001CPUS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	Andersen, Raymond J. et al., "Total Synthesis of (-)-Hemiasterlin, a Structurally Novel Tripeptide that Exhibits Potent Cytotoxic Activity," *Tetrahedron Letters,* Vol. 38(3):317-320 (1997)	
	C2	Bhatnagar, Pradip Kumar et al., CAplus AC 1999:811016, "Compositions and methods using glycinamide-containing peptide for expansion of hematopoietic cells," (2006)	
	C3	Billson, Jeremy et al., "The Design and Synthesis of Inhibitors of the Cysteinyl Protease, *DERPI,*" *Bioorgiinic & Medicinal Chemistry Letters,* Vol. 8:993-998 (1998)	
	C4	Dragovich, Peter S. et al., "Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure-Activity Studies," *J. Med. Chem.,* Vol. 41:2806-2818 (1998)	
	C5	Hauske, James R. et al., "Design and Synthesis of Novel FKBP Inhibitors," *J. Med. Chem.,* Vol. 35:4284-4296 (1992)	
	C6	Jones, Iwan G. et al., "The use of norbornene derivatives in the synthesis of conformationally constrained peptides and pseudo-peptides," *Letters in Peptide Science,* Vol. 5:171-173 (1998)	
	C7	Kovacs, Gabor L. et al., CAplus AC 1989:400176, "Antiamnesic effects of D-pipecolic acid and analogs of Pro-Leu-Gly-NH2 in rats," (1998)	
	C8	Kovács, Gábor L. et al., "Antiamnesic Effects of D-Pipecolic Acid and Analogues of Pro-Leu-Gly-HN_2 in Rats," *Pharmacology, Biochemistry & Behavior,* Vol. 31:833-837 (1989)	
	C9	Martha, P.M. et al., "Prolonged Suppression of Circulating Estrogen Levels Without an Initial Hormonal Flare Using Abarelix-Depot, a Pure GnRH Antagonist in Women With Endometriosis," *Fertility and Sterility,* Vol. 72(6):S210-S211, No. P-375 (1999)	
	C10	Nieman, James A. et al., "Synthesis and Antimitotic/Cytotoxic Activity of Hemiasterlin Analogues," *J. Nat. Prod.,* Vol. 66:183-199 (2003)	
	C11	Politi, Vincenzo, et al., CAplus AC 1997:244196, "Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof," (1997)	
	C12	Sato, Yoshinari et al., CAplus AC 1996:353193, "Preparation of benzodiazepines as cholecystokinin B antagonists," (1996)	
	C13	Szabo, Gyula et al., CAplus AC 1985:179250, "Effects of oxytocin fragment and its analogs on brain monoamine levels in rat brains," (1985)	
	C14	Szabó, Gyula et al., "Effects of Ocytocin Fragment and its Analogs on Brain Monoamine Levels in Rat Brains," *Neuropeptides and Psychosomatic Processes, Int. Conf. Integr. Neurohumoral Mech., Meeting,* pgs. 195-200 (1983)	

Examiner Signature		Date Considered	